In vitro assays demonstrate that royal jelly reduces cancer cell proliferation in colorectal cancer, suggesting therapeutic potential due to bioactive compounds.
Key Points
To evaluate the antiproliferative effects of royal jelly on colorectal cancer cell lines and its bioactive components.
Evaluated antiproliferative effects on colorectal cancer cell lines HCT-116 and DLD-1.
Conducted in vitro assays to measure cancer cell proliferation and cytotoxicity towards normal epithelial cells (FHC).
Performed multivariate analyses including principal component and hierarchical cluster analysis.
Demonstrated dose-dependent inhibition of cancer cell proliferation.
Observed limited cytotoxicity towards normal epithelial cells, indicating selective activity.
Identified positive correlations between higher levels of 10-HDA and acidity with enhanced antiproliferative effects.